التفاصيل البيبلوغرافية
| العنوان: |
Pharmacokinetics of Pamidronate in Patients With Bone Metastases |
| المؤلفون: |
Leyvraz, S., Hess, U., Flesch, G., Bauer, J., Hauffe, S., Ford, J. M., Burckhardt, P. |
| سنة النشر: |
2017 |
| المجموعة: |
réro doc Digital Library (Library Network of Western Switzerland / Réseau des bibliothèques de Suisse occidentale) |
| الوصف: |
Background: Pamidronate is a secondgeneration bisphosphonate used in the treatment of tumor-induced hypercalcemia and in the management of bone metastases from breast cancer, myeloma, or prostate cancer. The pharmacokinetics of pamidronate is unknown in cancer patients. Purpose: To determine the influence of the rate of administration and of bone metabolism, we studied the pharmacokinetics of pamidronate at three different infusion rates in 37 patients with bone metastases. Methods: Three groups of 11-14 patients were given 60 mg pamidronate as an intravenous infusion over a period of 1, 4, or 24 hours. Urine samples were collected in the three groups of patients. Plasma samples were obtained only in the 1-hour infusion group. The assay of pamidronate in plasma and urine was performed by high-performance liquid chromatography with fluorescence detection after the derivatization of pamidronate with fluorescamine. Results: The body retention (BR) at 0-24 hours of pamidronate represented 60%-70% of the administered dose and was not significantly modified by the infusion rate. In particular, the BR at 0-24 hours was not reduced at the fastest infusion rate. Among patients, a threefold variability in BR at 0-24 hours occurred, which was related directly to the number of bone metastases and, to some extent, to creatinine clearance. At 60 mg/hour, the plasma kinetics followed a multiexponential course characterized by a short distribution phase. The mean (±SD) half-life of the distribution phase was 0.8 hour (±0.3), the mean (±SD) of the area under the curve for drug concentration in plasma × time at 0-24 hours was 22.0 × 8.8 μmol/L × hours, and the mean (±SD) of the maximum plasma concentration was 9.7 μmol/L (±3.2). Pharmacokinetic variables remained unchanged after repeated infusions applied to four patients. Clinically, the three infusion rates were equally well tolerated without significant toxicity. Conclusions: The 1-hour infusion rate could be proposed as kinetically appropriate for the administration ... |
| نوع الوثيقة: |
other/unknown material |
| اللغة: |
English |
| العلاقة: |
http://doc.rero.ch/record/290885/files/84-10-788.pdfTest |
| الإتاحة: |
http://doc.rero.ch/record/290885/files/84-10-788.pdfTest |
| رقم الانضمام: |
edsbas.85EE1DFD |
| قاعدة البيانات: |
BASE |
